Nutra Pharma Corporation reached a settlement with the U.S. Securities and Exchange Commission (?SEC?). On March 19, 2024, the United States District Court for the Eastern District of New York in SEC v. Nutra Pharma Corporation, Erik Deitsch a/k/a Rik Deitsch, and Sean Peter McManus, Case No. 1:18-cv-05459-JS (E.D.N.Y.), approved bifurcated settlements in the form of consent judgments (the ?Consent Judgments?) entered by the Court, wherein the Defendants, without admitting or denying the allegations of the Complaint except as to personal and subject matter jurisdiction, resolved all liability issues and certain remedies as to each Defendant and left open other issues relating to remedies regarding the appropriateness and amount of disgorgement and/or civil penalties to be paid as to all Defendants, and whether a penny stock bar shall be imposed against Defendant McManus, and if so, the length of any such bar, for later resolution by the Court upon motion or further settlement.

Pursuant to its settlement with the SEC, Rik J Deitsch tendered resignation as Chairman of Nutra Pharma Corp. effective March 19, 2024. The Company?s former CEO, Dr. Michael Flax, will resume this position effective immediately.

Following his resignation as an officer and director of the Company, its Board of Directors has appointed Mr. Deitsch to the position of Operations Manager: reporting to Joe Lucas, VP of Operations.